Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 28, 2015 02:39 ET | Source: Active Biotech

Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod presented at the ECC conference

LUND, Sweden, Sept. 28, 2015 (GLOBE NEWSWIRE) -- Active Biotech (NASDAQ STOCKHOLM: ACTI) today announces, at the European Cancer Congress (ECC 2015) held in Vienna 25-29 September, the presentation of...
September 28, 2015 02:30 ET | Source: Active Biotech

Final results from Active Biotech's 10TASQ10 Phase 3 study of tasquinimod presented at the ECC conference

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund (Sweden) 28 September 2015 - Active Biotech...
September 28, 2015 02:30 ET | Source: Active Biotech

Finala resultat från Active Biotechs tasquinimod fas 3-studie 10TASQ10 presenteras på konferensen ECC

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Lund den 28 september 2015 - Active Biotech...
August 07, 2015 02:38 ET | Source: Active Biotech

Active Biotech AB Interim report January - June 2015

LUND, Sweden, Aug. 7, 2015 (GLOBE NEWSWIRE) -- Operations focused on the laquinimod projects and organization adjusted accordingly Laquinimod The pivotal CONCERTO clinical Phase III...
August 07, 2015 02:30 ET | Source: Active Biotech

Active Biotech AB Delårsrapport januari - juni 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} · Verksamheten fokuseras på laquinimod-projekten...
August 07, 2015 02:30 ET | Source: Active Biotech

Active Biotech AB Interim report January - June 2015

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} · Operations focused on the laquinimod...
June 25, 2015 08:27 ET | Source: Active Biotech

Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial

Jerusalem & Lund, Sweden, June 25, 2015 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Active Biotech (NASDAQ Stockholm: ACTI) today announced that the patient...
June 25, 2015 08:00 ET | Source: Active Biotech

Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Jerusalem & Lund, Sweden - June 25,...
June 25, 2015 08:00 ET | Source: Active Biotech

Teva och Active Biotech meddelar att fas III-studien CONCERTO med laquinimod är fullrekryterad

body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Jerusalem, Israel och Lund, Sverige den...
June 12, 2015 02:33 ET | Source: Active Biotech

Annual General Meeting of Active Biotech AB

LUND, Sweden, June 12, 2015 (GLOBE NEWSWIRE) -- The Annual General Meeting of Active Biotech was held on June 11, 2015. In accordance with the Board of Directors' proposal, it was resolved that no...